Ultrafiltration for Kidney Failure
(DRIVE-UF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease. This extra fluid is the main cause of high blood pressure in dialysis and leads to stress on the heart and lungs.that causes debilitating symptoms and frequent hospitalizations.
This trial will test whether a focused program of 4 or 8 weeks of extra ultrafiltration treatments can remove most of this extra fluid. We believe that getting rid of large amounts of extra fluid will result in sustained improvements in blood pressure and symptoms. Ultrafiltration is a gentler type of dialysis that removes fluid but does not clean the blood.
Who Is on the Research Team?
Bryan Kestenbaum, MD, MS
Principal Investigator
University of Washington
Are You a Good Fit for This Trial?
This trial is for people with kidney failure who are on hemodialysis and have problems with extra fluid in their body, such as swelling or high blood pressure. Participants should be able to safely undergo additional fluid removal sessions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a four-week or eight-week ultrafiltration strategy, or continue regular hemodialysis treatments
Follow-up
Participants are monitored for changes in blood pressure and symptoms of congestion
What Are the Treatments Tested in This Trial?
Interventions
- Ultrafiltration
Trial Overview
The study tests whether doing extra ultrafiltration treatments over 4 or 8 weeks can remove more excess fluid than usual care, aiming to improve blood pressure and reduce symptoms related to too much fluid.
How Is the Trial Designed?
3
Treatment groups
Active Control
Two ultrafiltration sessions per week plus pharmacist guided tapering of blood pressure medications in addition to the regular thrice weekly hemodialysis treatments.
Two ultrafiltration sessions per week plus pharmacist guided tapering of blood pressure medications in addition to the regular thrice weekly hemodialysis treatments.
Participant receives only their regularly scheduled thrice weekly hemodialysis treatments.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.